
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is at an inflection point because its core Life Sciences Services business has delivered about six straight quarters of 15% to 20% year-over-year growth, now represents 57% of revenue, and is benefiting from rising commercial CGT adoption as 22 approved therapies and 94 Phase 3 trials expand the recurring revenue base. In 2Q:26, the company generated $49 million of revenue, posted positive adjusted EBITDA of $0.4 million for the first time since 1Q:23, and produced about $5 million of positive operating cash flow in 1H 2026, signaling improving scale and operating leverage. Its outlook is further strengthened by higher-value catalysts such as BioStorage/BioServices growth, the IntegriCell rollout, and upcoming Paris and Santa Ana facility launches in Q4 2026, while MVE and new freezer products add resilience and optionality.
Bears say
CryoPort is facing a less attractive fundamental setup as growth in its core cell and gene therapy end market depends on a slower-than-expected pace of approvals, which management and the bear case note could weaken both revenue and profitability. Total revenue rose only 8% organically to $49M, with Life Sciences Services up 15% to $28M but Life Sciences Products flat at $21M and missing consensus, highlighting uneven demand and softness in the higher-risk Products business. Ongoing macro pressure on MVE, competition in cold-chain logistics, and the possibility of fewer commercial product flows all threaten margins and could keep valuation under pressure.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares